

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/OUTCOME/2018-19

Date: 25th July, 2018

BSE Limited

Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting.

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results of the Company for the quarter ended on June 30, 2018 as **Annexure-A** and
- b) Limited Review Report on the Un-Audited Financial Results as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- c) Approved draft Annual Report for the financial year 2017-18.
- d) Approved Re-classification of NIAM International Private Limited as non-promoter entity of the Company.
- e) An Investor Release dated 25th July, 2018 on the financial results is enclosed at **Annexure-C**.
- f) Appointment of Mr. Pratap Singh Rawat as Chief Financial Officer & Key Managerial Personnel of the Company.

The meeting of the Board of Directors commenced on 11:00 am and concluded at 12:50 p.m.


The Un-Audited Financial Results of the Company for the quarter ended June 30, 2018, as approved by the Board, will also be available on the Company's website at www.medicamen.com.


This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS- 44157



MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

Un-audited Standalone Financial Results for the quarter ended on 30th June 2018

PART I

Particulars		Rupees in Lacs (Except per Share data)			
		Quarter Ended			Year Ended
		3 Months Ended 30/06/2018 Unaudited	Preceding 3 Months Ended 31/03/2018 Audited	Corresponding 3 Months Ended 30/06/2017 Unaudited	Year Ended 31/03/2018 Audited
1	Income from operations				
	(a) Net Sales/Income from operations (Net of excise duty)	3,276.34	2,930.08	2,600.69	11,150.72
	(b) Other Income	116.29	99.83	32.60	188.79
	(c) Total Revenue	3,392.63	3,029.91	2,633.29	11,339.51
2	Expenses				
	a) Cost of Material Consumed	1,934.20	1,864.82	1,628.77	6,878.24
	b) Purchase of Stock-in-Trade	-	-	-	0.05
	c) Changes in inventory of Finished Goods and Work in Progress	262.45	50.07	(51.35)	(113.07)
	d) Employees Benefits Expenses	216.79	187.17	212.89	905.30
	e) Finance Cost	35.77	51.05	54.06	240.81
	f) Depreciation and Amortisation Expenses	47.70	49.88	48.06	205.79
	g) Other expenses	441.73	449.80	427.49	1,832.38
	Total Expenses	2,938.64	2,652.79	2,319.92	9,949.51
3	Profit/(Loss) before Exceptional Items & Tax (1-2)	453.99	377.12	313.37	1,390.00
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	453.99	377.12	313.37	1,390.00
6	Tax Expenses				
	Current Year	133.71	195.26	63.89	401.78
	Deferred Tax Liability	(1.92)	(4.38)	(1.13)	(23.05)
	Total Tax Expenses	131.79	190.88	62.76	378.73
7	Net Profit/Loss for the period (5-6)	322.20	186.24	250.61	1,011.27
8	Other Comprehensive Income				
	Item that will not be reclassified to Profit & Loss	-	-	-	-
	Total Comprehensive income Net of Tax	322.20	186.24	250.61	1,011.27
9	Total Comprehensive income for the Period (7+8)	322.20	186.24	250.61	1,011.27
10	Paid-up equity share capital (Rs.10/- per share)	1,170.00	1,170.00	1,107.00	1,170.00
11	Earning Per Share (Rs.)				
	(a) Basic	2.75	1.66	2.28	9.03
	(b) Diluted	2.75	1.66	2.28	9.03

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 25th, Jul, 2018.
- The figures are regrouped in previous year also, wherever considered necessary.
- The company operates only in one business segment, viz. Pharmaceuticals Formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33- "Earning per share"
- Limited review Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : Delhi

Dated : 25.07.2018

Independent Auditor's Review Report on Standalone Quarterly Financial Results

To


The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43,
Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of **MEDICAMEN Biotech Limited** for the quarter ended 30th June, 2018 being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants



QIMAT Rai Garg
Partner
(Membership No. 080857)

Place: Gurgaon
Date: 25.07.2018



Medicamen Biotech Limited

Q1 FY19 Presentation
July 2018

Agenda




Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Medicamen Biotech Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Quarterly Highlights


Net sales

26.0%
growth




EBIT

33.5%
growth



Net profit

28.3%
growth



Note: in INR Lakhs

Profit and Loss Summary for Y-o-Y Performance

Particulars	1Q FY19 (INR lakhs)	% of net sales	1Q FY18 (INR lakhs)	% of net sales	Y-o-Y growth
Net Sales	3,276.34		2600.69		26.0%
EBITDA	537.46	16.4%*	415.49	16.0%*	29.4%
EBIT	489.76	14.9%*	367.43	14.1%*	33.3%
Net Profit	322.20	9.8%*	250.61	9.6%*	28.6%
EPS (in INR)	2.75		2.28		20.6%

Note: * margins calculated using net sales

Strategy and Outlook

Export oriented




- Shifting focus from domestic to export markets such as Africa, Latin America, CIS* and South East Asia

Portfolio realignment



- Focus on high margin formulations such as oncology, cardiovascular and anti-diabetic products (lifestyle diseases)

Capacity expansion



- Construction of new plant for Oncology formulation products (Haridwar) and upgradation of existing plant (Bhiwadi) including R&D centre

Future outlook:

Medicamen striving to expand share of exports in total income from 80% to 90%

Note: *Commonwealth of Independent States



Upcoming Oncology formulation plant at Haridwar (Unit II)



Appendix

Company Overview

Snapshot


Incorporation Year: 1993

Corporate office: New Delhi


Employees: Over 225 (as of 31 March 2018)

Exchange Listing: BSE

Shareholding Pattern (as of 30 June 2018):



Product offerings



Manufacturing sites



Bhiwadi
(Rajasthan)

Area: 4.8 acre



Haridwar
(Uttarakhand)

Area: 0.74 acre

Global Footprint

Plant approvals globally

Americas

- ▶ Brazil
- ▶ Costa Rica
- ▶ Cuba
- ▶ Dominican Republic
- ▶ El Salvador
- ▶ Guatemala
- ▶ Honduras
- ▶ Nicaragua
- ▶ Panama

Africa

- ▶ Algeria
- ▶ Benin
- ▶ Botswana
- ▶ Burkina Faso
- ▶ Cameroon
- ▶ Chad
- ▶ Congo
- ▶ Ethiopia
- ▶ Gabon
- ▶ Ghana
- ▶ Guinea
- ▶ Ivory cost
- ▶ Kenya
- ▶ Lesotho
- ▶ Malawi
- ▶ Mali
- ▶ Namibia
- ▶ Nigeria
- ▶ Rwanda
- ▶ South Sudan
- ▶ Tanzania
- ▶ Uganda
- ▶ Zambia
- ▶ Zimbabwe

Asia Pacific*

- ▶ Afghanistan
- ▶ Bhutan
- ▶ Kyrgyzstan
- ▶ Myanmar
- ▶ Nepal
- ▶ Philippines
- ▶ Sri Lanka
- ▶ Vietnam

Note: *Afghanistan and Kyrgyzstan are part of CIS nations

Detailed Profit and Loss Statement

In INR Lakhs

Particulars	3 months ended 30 June 2018 (unaudited)	3 months ended 31 Mar 2018 (audited)	3 months ended 30 June 2017 (unaudited)	Year ended 31 Mar 2018 (audited)
Income from operations				
Net sales/income from operations	3,276.3	2,930.1	2,600.7	11,150.7
Other income	116.3	99.8	32.6	188.8
Total Revenue	3,392.6	3,029.9	2,633.3	11,339.5
Expenses				
Cost of material consumed	1,934.2	1,864.8	1,628.8	6,878.2
Purchase of goods traded	-	-	-	0.1
Changes in inventory of finished goods and WIP	262.5	50.1	-51.4	-113.1
Employee benefit expenses	216.8	187.2	212.9	905.3
Finance Cost	35.8	51.1	54.1	240.8
Depreciation and Amortization expenses	47.7	49.9	48.1	205.8
Other expenses	441.7	449.8	427.5	1,832.4
Total Expenses	2,938.6	2,652.8	2,319.9	9,949.5
Profit / (Loss) before Exceptional items and tax	454.0	377.1	313.4	1,390.0
Exceptional items (Commercial tax expenses for prior years)	-	-	-	-
Profit / (Loss) before tax	454.0	377.1	313.4	1,390.0
Tax expenses:				
Current year	133.7	195.3	63.9	401.8
Deferred Tax Liability	-1.9	-4.4	-1.1	-23.1
Net Profit / (Loss) for the period before minority interest	322.2	186.2	250.6	1,011.3
Share of profit / (loss) of associates	-	-	-	-
Minority interest	-	-	-	-
Net Profit / (Loss) after taxes and minority interest	322.2	186.2	250.6	1,011.3
Paid up equity share capital (Rs 10 per share)	1,170.0	1,170.0	1,107.0	1,170.0
Earnings per share (Rs)				
Basic	2.8	1.7	2.3	9.0
Diluted	2.8	1.7	2.3	9.0



Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: vk@medicamen.com

Website: www.medicamen.com